Use of truncated cysteine il28 and il29 mutants to treat...

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 38/20 (2006.01) A61P 1/00 (2006.01) A61P 17/06 (2006.01) A61P 19/02 (2006.01) A61P 25/00 (2006.01) A61P 35/00 (2006.01) A61P 43/00 (2006.01)

Patent

CA 2616004

Methods for treating patients with cancer and autoimmune disorders using IL-28 and IL-29 molecules. The IL-28 and IL-29 molecules include polypeptides that have homology to the human IL-28 or IL-29 polypeptide sequence and proteins fused to a polypeptide with IL-28 and IL-29 functional activity. The molecules can be used as a monotherapy or in combination with other known cancer and/or autoimmune therapeutics.

L'invention concerne des méthodes de traitement de patients atteints de cancer et de troubles autoimmuns à l'aide de molécules d'IL-28 et d'IL-29. Les molécules d'IL-28 et d'IL-29 comprennent des polypeptides qui présentent une homologie avec la séquence de polypeptides d'IL-28 ou d'IL-29 humains et des protéines fusionnées avec un polypeptide présentant une activité fonctionnelle d'IL-28 et d'IL-29. Lesdites molécules peuvent être utilisées en tant que monothérapie ou en combinaison avec d'autres thérapies connues contre le cancer et les troubles autoimmuns.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Use of truncated cysteine il28 and il29 mutants to treat... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of truncated cysteine il28 and il29 mutants to treat..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of truncated cysteine il28 and il29 mutants to treat... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-2063711

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.